Articles tagged with Lymphoma
Researchers at Weill Cornell Medicine have identified mutations in the ARID1A gene that drive follicular lymphoma transformation into a more aggressive form. These mutations make patients highly susceptible to experimental BAF-inhibitor drugs, offering new hope for early intervention therapies.
A new AI model, called Lars, can accurately detect signs of lymph node cancer in 90% of cases, reducing workload for radiologists and increasing access to healthcare. The model was developed using a large dataset of over 17,000 images from 5,000 patients and is based on deep learning technology.
A recent study published in the Journal of Veterinary Medicine found no significant correlation between canine lymphoma and proximity to environmental toxins. Researchers used data from Morris Animal Foundation's Golden Retriever Lifetime Study to map dog home addresses to radon zones and fracking wells, but did not find a link.
Sezáry syndrome patients face a vicious circle where cancer and treatment weaken the immune system, allowing bacteria like S. aureus to thrive. Eliminating these bacteria may make cancer cells more susceptible to anti-cancer drugs.
Researchers from Brazil discuss the management of refractory or relapsed classic Hodgkin lymphoma in adults, highlighting novel agents such as brentuximab vedotin and immunotherapy. The Brazilian healthcare system's constraints are also considered when making treatment decisions.
A new study has identified protein expression patterns that can predict the progression of follicular lymphoma, an incurable type of cancer. By analyzing tumour samples from patients, researchers have found a correlation between specific proteins and disease transformation, enabling early detection of high-risk patients.
A phase 2 trial PrE0405 showed an 85% complete response rate in 33 patients over 60 with mantle cell lymphoma who received venetoclax combined with bendamustine and rituximab. The combination was generally well-tolerated, with gastrointestinal toxicities common.
A Stanford Medicine-led study identified circulating tumor DNA as a predictor of disease recurrence and grouped Hodgkin lymphoma into two subgroups with distinct genetic changes. This discovery may lead to more effective treatments with reduced toxicity.
Researchers have identified a common mutation in the transcription factor IRF4 that drives tumor cell development in Hodgkin's lymphoma. This mutation leads to the activation of disease-relevant genes, and blocking its effects could provide new therapeutic opportunities.
Men who are overweight or obese at age 18 have a higher risk of developing 17 different cancers later in life. Higher BMI is also associated with an increased risk of mortality after cancer diagnosis for certain types of cancer.
A recent study by UTHealth Houston found that the offspring of adolescent and young adult women with a history of cancer face a higher risk of birth defects. The study examined 6,882 offspring ages 12 months and younger and found an increased risk of specific types of defects in the offspring of women with a history of cancer.
Researchers found a 55% reduction in lymphoma risk and a 40% overall reduction in blood cancer risk among bariatric surgery patients. Women with high blood sugar at the start of the study benefited most from the surgery.
Dr. Hung Nguyen is studying how medium chain fatty acid foods like coconut oil and avocados affect GVHD severity and mortality in transplant patients. His goal is to develop a dietary approach that reduces inflammation and corticosteroid use, improving patient outcomes for blood cancers.
A multicenter team has identified three risk biomarkers for chronic graft-versus-host-disease, which can be measured at 90 days after transplantation. These markers include MMP3, DKK3, and CXCL9, which are associated with fibrosis, inflammation, and immune cell attraction.
Research by the University of Southampton found that repeated COVID-19 vaccine doses increase immune response in blood cancer patients, generating higher-quality antibodies. Booster vaccinations are essential for maintaining protection against COVID-19 in immunocompromised individuals.
Research found that women treated for childhood Hodgkin lymphoma may experience declining fertility and longer wait times to become pregnant, but overall success rates are high. The majority of women in the study who had tried to become pregnant were successful, with some being able to conceive at a younger age.
Researchers have created a new prediction tool to evaluate the benefits of blood cancer treatments, filling a gap in previous versions. The ESMO-MCBS:H v1.0 tool uses a validated algorithm to assess clinical benefits, survival data, and quality of life, providing a transparent assessment for clinicians.
Researchers have identified LP-284 as a novel acylfulvene compound with anti-tumor activity against non-Hodgkin's lymphoma. The compound exerts nanomolar potency in 15 NHL cell lines and prolongs survival of mantle cell lymphoma xenograft mice, making it a potential therapeutic option for patients with HR or TC-NER deficiency.
Researchers analyzed 23 pregnant women with relapsed/refractory lymphoma and found a 24% progression-free survival rate and an 83% overall survival rate. The study suggests that delays in treatment may allow cancer to progress, while initiating chemotherapy can harm the fetus.
A new Northwestern Medicine study found young adult cancer survivors (18-39 years old) are 2.6 times more likely to develop heart failure when treated with anthracyclines. The incidence is highest among leukemia and other specific cancer types.
A study of 7807 children found no increased risk of brain tumours, leukemia, or lymphoma after a single CT scan. However, exposure to 4 or more scans before adulthood significantly increases the risk of intracranial tumours, leukemia, and non-Hodgkin lymphoma
Researchers at Moffitt Cancer Center have identified a critical pathway in the development of MYC-driven lymphoma, involving the chemical modification of eIF5A with hypusine. Inhibiting this process prevents lymphoma development and progression in mouse models, offering new therapeutic strategies.
Researchers at Georgia Institute of Technology developed a synthetic tumor model to understand the impact of microenvironment on targeted therapies for Activated B Cell-like Diffuse Large B cell lymphoma. The model showed promise in demonstrating how combining therapeutics can overcome tumor resistance to inhibitors.
Researchers have found a new solution to combat resistant staphylococcus aureus infections, which can be difficult to treat. Endolysins, a newly developed enzyme, has been shown to kill both resistant and non-resistant staphylococcus aureus without the need for antibiotics.
A new study using whole genome sequencing identifies previously unknown mutations driving Hodgkin lymphoma development. The research provides temporal insights into tumor evolution, enabling more precise targeted treatment options.
Researchers have found that blood cancer tumours use signals to attract certain types of immune cells and instruct them not to attack. High concentrations of these cell clusters predict treatment failure, but a different microenvironment is associated with treatment success.
A new study found that the antibody-drug conjugate STRO-001 showed nanomolar cytotoxicity in 88% of cancer cell lines tested, with potent efficacy against proliferating B cells. The research supports ongoing clinical studies for patients with B-cell non-Hodgkin lymphoma.
Researchers at Australian National University and Peter MacCallum Cancer Centre found that targeting the Menin protein can reactivate dormant genes, making cancer cells visible to the immune system. This discovery could lead to more effective treatments for lymphoma and lung cancer by combining Menin inhibitors with existing therapies.
Researchers describe results using cladribine-based combination epigenetic and immunotherapy in MCL, achieving an increased overall survival greater than 40 months with durable remissions without relapse for longer than 5 years. The approach is promising in the treatment of MCL and potentially other previously treatment-refractory canc...
A new Columbia University study has found that breast implants after mastectomy are associated with an extremely low risk of developing a rare cancer called anaplastic large-cell lymphoma (ALCL). According to the study, only five cases of ALCL were diagnosed among 57,000 women who had undergone reconstructive surgery over 421,000 years...
A systematic review of national clinical practice guidelines in Europe found that fewer than half include HIV testing recommendations for patients with medical conditions indicating HIV infection. This omission hinders efforts to stop the spread of HIV through timely diagnosis, affecting the lives of people living with HIV.
Researchers at Weill Cornell Medicine found a new way to target mantle cell lymphoma by inhibiting the activity of FOXO1 protein, which coordinates gene expression. The discovery could lead to new treatments and improved understanding of how this type of lymphoma develops.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
A multicenter clinical trial showed that combining brentuximab vedotin with standard chemotherapy reduced event-free survival by 10%, decreasing relapse risk. This targeted therapy approach may set the stage for FDA approval and improve cure rates without adding significant long-term toxicity.
A multistate study found that mRNA COVID vaccines were less effective in immunocompromised adults, with protection rates ranging from 34% to 71% after multiple doses. The study emphasizes the importance of non-pharmaceutical interventions, such as masks and antibody treatment, for additional protection against severe COVID-19.
Researchers at the University of South Australia are using new technologies to speed up blood cancer diagnosis and treatment. The project aims to identify genetic variants that cause cancer, enabling clinicians to provide targeted treatments and improve patient management.
The NCCN Annual Congress on Hematologic Malignancies will address key findings on chronic lymphocytic leukemia management and CAR T-cells in diffuse large B-cell lymphoma. The event also features updates on immunotherapies in multiple myeloma treatment.
Researchers found that 12% of cancer survivors lived in poverty, experiencing negative effects on physical and mental health. Financial burden of cancer care persists years after diagnosis, leading to poor health outcomes and increased mortality.
Scientists discover that methotrexate causes oxidative damage to the cerebrospinal fluid and choroid plexus, leading to cognitive impairment. Adding antioxidants to the CSF may protect against this damage, offering a potential treatment for 'chemo brain'. Researchers are exploring other chemotherapy drugs and testing antioxidant treatm...
Scientists at St. Jude Children's Research Hospital studied 36 families affected by Hodgkin lymphoma and identified 44 novel genetic variants linked to cancer predisposition, including PAX5, GATA3, IRF7, EEF2KMT, and POLR1E. The study provides new insights into the disease and may help identify potential targets for new treatments.
Researchers have identified a potential new therapeutic approach for angioimmunoblastic T-cell lymphoma (AITL) by understanding the mechanism of its development. A team from the University of Tsukuba found that B cells accumulate mutations in genes controlling genetic material packaging, leading to AITL.
Researchers developed a method to produce generic CAR T cells from induced pluripotent stem cells (iPS cells), which could be produced at scale for multiple patients. The new cells showed enhanced anti-tumor activity and comparable efficacy to current clinical-grade cells.
A recent study published in CANCER highlights the growing concern among Hodgkin lymphoma survivors. The analysis found that individuals with early-stage HL are now at a higher risk of death from cardiovascular disease compared to cancer after approximately 60 and 120 months of follow-up. This indicates that more effective measures are ...
Researchers from Mayo Clinic Comprehensive Cancer Center found that adding brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma. The study showed that the drug has a positive impact on overall survival, regardless of other treatments administered later in the course of care.
This analysis evaluated changes in short-course radiation therapy use and spending on low-grade lymphoma patients from 2015 to 2019. The study found a significant increase in the use of this therapy among Medicare beneficiaries, suggesting potential cost savings and improved patient outcomes.
The study found that autologous stem cell transplantation (ASCT) was underutilized in community settings, but maintenance therapy after standard therapy improved outcomes for patients over 65. Maintenance rituximab after bendamustine and chemotherapy regimens also significantly extended times to disease progression and overall survival.
The study found that combination chemoimmunotherapy with ibrutinib improved progression-free survival over standard chemoimmunotherapy in patients with previously untreated mantle cell lymphoma. The median PFS was 80.6 months with the ibrutinib combination versus 52.9 months in the control arm.
MD Anderson research highlights new treatments for skin cancers, including novel therapies. The institution also showcased improved goals of care programs, which demonstrated significant reductions in ICU mortality and improved patient outcomes during the COVID-19 pandemic.
A population-scale study found COVID-19 vaccination is effective in most cancer patients but offers lower protection and wanes quickly. Vaccine effectiveness was lower (65.5%) in cancer patients compared to the general population (69.8%), with higher hospitalization and death risks despite vaccination.
A new lymphoma treatment, zanubrutinib, has been found to be effective in 80% of patients with marginal zone lymphoma, resulting in significant cancer shrinkage. However, its impact on follicular lymphoma is less pronounced.
A study published by Mayo Clinic Cancer Center investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with CAR-T cell therapy. The team found that a gene called TIGIT drives CAR-T cell exhaustion and dysfunction, suggesting its blocking strategy may improve treatment efficacy.
The study found significant heterogeneity among non-hematopoietic cells (NHCs) in human lymph nodes, with subgroups exhibiting distinct transcriptional changes and interaction patterns with malignant cells. This discovery may lead to the identification of potential biomarkers for therapeutic approaches.
Patients with serious illnesses seek cosmetic procedures to maintain their physical and mental well-being, as well as to become comfortable in social settings. The study found that these procedures are often chosen for noninvasive treatments and endorsed by doctors, friends, and family.
Dr. Elaine S. Jaffe is being recognized for her pioneering work in hematopathology, including the discovery of novel pathological entities and her development of standardized diagnostic criteria for lymphoma and leukemia. She has also made significant contributions to advancing cancer research, diagnosis, treatment, and prevention.
A new study by University of Southampton researchers found that a third COVID-19 vaccination improves immune responses in blood cancer patients. The study showed that 92% of patients without recent anti-CD20 treatment had improved antibody responses after the third dose.
Scientists have identified diagnostic features of circulating tumour DNA (ctDNA) in blood samples, which can predict treatment response and patient outcome in aggressive lymphoma. The study reveals significant heterogeneity among patients, with high ctDNA levels associated with poorer survival rates.
A new blood test developed at Hebrew University of Jerusalem detects immune and inflammatory activity in tissues by monitoring circulating DNA fragments. This method provides accurate information about immune processes in remote tissues, removing the need for invasive measures.
Researchers at the University of Texas MD Anderson Cancer Center demonstrated axi-cel's efficacy in treating high-risk lymphoma patients with enhanced responses and prolonged survival benefits. The study showed improved outcomes for patients with indolent non-Hodgkin lymphoma, with an estimated 81% overall survival rate at 24 months.
A recent study by NTU Singapore and Singapore General Hospital found that mutations in the DDX3X gene are responsible for chemotherapy resistance in some blood cancer patients. The study also discovered that STAT inhibitors can effectively kill lymphoma cells with DDX3X mutations, providing hope for new treatment options.
A new treatment target for lymphoma has been identified as protein KDM5, which may reverse the effects of KMT2D mutations in cancer cells. The international collaboration aims to identify patient groups most likely to benefit from this type of treatment and explore its therapeutic potential across various lymphoma subtypes.